European Respiratory Journal

Article	Citations
The right ventricle tamed	1169
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	882
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	741
Chymase-1: a “MAST”-er switch in COPD?	359
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	229
Missing airways, ventilation defects and conductive airway physiology in asthma	221
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	199
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	181
A breath of the future: a novel human model for COPD and beyond	158
The lung that rules the heart	149
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	146
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	144
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	142
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	137
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD	129
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	124
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al	123
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	123
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	123
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	116
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	108
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	105
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	103
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	101
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	98

Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	94
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	93
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	93
Soteria: deliverance from harm?	91
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	91
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	89
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	88
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	86
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	84
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	81
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	80
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	80
Treatment algorithm for pulmonary arterial hypertension	80
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	80
The environmental impact of inhaled therapy: making informed treatment choices	79
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	79
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	78
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	78
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	78
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	76
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	74
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	72
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	71
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	69
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	67
Childhood asthma: pathogenesis and phenotypes	66
Prognostic phenotypes of early-stage lung adenocarcinoma	65
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	65
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	64
The limits of normal of pulmonary arterial wedge pressure	64
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	63
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	63
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	63
Pleural mesothelioma: surgery questioned again?	62
List ofEuropean Respiratory Journalpeer reviewers 2023	60
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	60
FEV1Q: what (even) is normal lung function?	58
The efficacy of singingversusexercise training: do the data really support the authors’ conclusions?	58
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander,et al.Eur Respir J2023; 62: 2300011.	58
The association between immunosuppressants and outcomes of COVID-19	58
Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis	57
The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation	56
Particulate matter–related ITIH4 deficiency is associated with an emphysema phenotype of chronic obstructive pulmonary disease through JNK-dependent and JNK-independent signaling	56
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	55
CPAP recall and cancer risk: should we be concerned?	55
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	52
Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study	52
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	51
WHO online guide on the use of digital technologies for tuberculosis programmes	51
Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures	51

Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis	50
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines	50
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	49
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis	49
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	49
Early-life exposure to mixture of phenols and respiratory health in pre-school children	48
Theratyping in cystic fibrosis: filling the knowledge gaps	48
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis	47
Small extracellular vesicles and induction of epithelial to mesenchymal transition in lymphangioleiomyomatosis	47
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac indexversusstroke volume index	47
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients	46
Oral corticosteroids in asthma and beyond: moving forward	45
Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!	45
Unravelling the unmet needs of patients with severe dyspnoea: a case for palliative oxygen	45
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	45
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain	45
Oxygen therapy target ranges: finding the balance	45
Reply to: Cause or consequence?	44
Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis	44
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease	44
Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism: results from the REVERSE study	43
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia	43
Cardiopulmonary response to exercise in adults born very preterm	43
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study	43
ERJPodcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma	43
Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?	43
Multitasking within the airway epithelium	42
COVID-19 changed the world – without changing CTEPH	42
Bronchoconstriction with inhaled ATP in healthy volunteers	42
Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants	41
ERJPodcast January 2024: The microbiome in early life and childhood asthma	41
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography	41
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry	40
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema	40
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease	40
Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999–2002	40
Filters used for pulmonary function testing	40
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system	39
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations	39
Is tezepelumab more than just an anti-eosinophil drug?	38
Transcriptomic clustering of critically ill COVID-19 patients	38
Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis	38
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA	38
Flavonoid intakes inversely associate with COPD in smokers	38
Metabolomics in pulmonary medicine: extracting the most from your data	37
Air pollution and COPD: GOLD 2023 committee report	37
Indoor microbiome, microbial and plant metabolites, chemical compounds, and asthma symptoms in junior high school students: a multicentre association study in Malaysia	37
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	37
European Respiratory Society guidelines for the diagnosis of asthma in adults	36
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	36
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases	36
Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content	35
Presenting clinical data for the hazard classification of chemical respiratory sensitisers	35
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism	35
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud	35
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study	35
Spirometry forced expiratory time is driven by airflow limitation in asthmatic children	35
Moving the dial on identifying endotypes of asthma from early life	35
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−1	34
Lung function during and after acute respiratory infection in COVID-19 positive and negative outpatients	34
Asthma, COPD and their overlap: coexistence or something more?	34
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle	34
Aspergillussensitisation: an underappreciated treatable trait in airway disease	34
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study	34
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!	34
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways	34
Relieving dyspnoea through the brain	34
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance	33
Lung transplantation for acute respiratory distress syndrome: a retrospective European cohort study	33
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned	33
The role of precision medicine in interstitial lung disease	33
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background	33
Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series	33
Primary spontaneous pneumothorax: does size matter?	33
Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy	33
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma	33
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health	32
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles	32
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis	32
Technical standards for respiratory oscillometry and bronchodilator response cut-offs	32

Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus	32
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis	32
Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis	31
Pulmonary hypertension associated with left heart disease	31
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–2016	31
Ex vivodelivery of regulatory T-cells for control of alloimmune priming in the donor lung	31
Evolving diagnostic techniques in mediastinal lymphadenopathy: is mediastinal cryobiopsy the new kid on the block?	31
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort	31
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium	30
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi	30
Incidence of interstitial lung abnormalities: the MESA Lung Study	30
Developing, validating, updating and judging the impact of prognostic models for respiratory diseases	30
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care	30
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement	30
The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands	29
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma	29
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis	29
Association of blood trihalomethane concentrations with asthma in US adolescents: nationally representative cross-sectional study	29
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance	29
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse	29
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?	29
List ofEuropean Respiratory Journalpeer reviewers 2022	29
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study	29
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.	29
ERJPodcast December 2023: Year in review	28
Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology	28
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flowFENO?	28
ERJPodcast July 2023: The HISTORIC study	28
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?	28
Ensuring availability of respiratory medicines in times of European drug shortages	28
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough	28
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?	28
Development and validation of a predictive 6-minute walk score in patients with Idiopathic Pulmonary Fibrosis	27
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension	27
Genetic associations between Serotonin Receptor 1F (HTR1F) regulatory variation and sleep apnea in non-obese individuals: Insights from GWAS and eQTL analyses	27
Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis	27
All roads lead to COPD… or not?	27
Management of pulmonary hypertension in special conditions	26
Sleep apnoea in the elderly: a great challenge for the future	26
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial	26
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges	26
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension	26
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial	25
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study	25
ERS statement on paediatric long-term noninvasive respiratory support	25
Integrating hot topics and implementation of treatable traits in asthma	25
Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside	25
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum,et al.Eur Respir	25
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study	25
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury	25
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-19	25
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice	25
Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries	25
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis	25
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study	25
A randomised trial of prednisoloneversusprednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma	25
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children	25
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)	25
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing	24
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection	24
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	24
Progressive pulmonary fibrosis: an expert group consensus statement	24
The interface in home non-invasive ventilation: is the nasal mask better?	24
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial	24
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis	24
Heart or lungs? Why not both!	24
Drug-induced lung disease: unwanted collateral damage	23
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer	23
Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesis	23
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter,et al.Eur Respir J2021; 58: 2004314	23
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash,et al.Eur Respir J2022; 60: 2101814	23
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!	23
Latent COPD: a proposed new term in the disease nomenclature	23
MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease	23
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials	23
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden	23
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis	23
Mycobacterium aviumcomplex genomics and transmission in a London hospital	23
How do people with COPD walk? A European study on digitally measured real-world gait	22
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease	22
Right heart function during and after pregnancy in women with pulmonary arterial hypertension	22
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension	22
Impact of a rare respiratory diseases reference centre set-up on primary ciliary dyskinesia care pathway	22
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9%versus3%versus6% nebulised saline	22
Genome-wide association study of susceptibility toPseudomonas aeruginosainfection in cystic fibrosis	22
Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic	22
CPAP resumption after a first termination and impact on all-cause mortality in France	22
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors	22
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults	22
Vulnerability to acid reflux of the airway epithelium in severe asthma	22
The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study	22
Increasing physical activity in severe asthma: a systematic review and meta-analysis	22
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?	22
Is long COVID an autoimmune disease?	21
Cytokines as prognostic biomarkers in pulmonary arterial hypertension	21